Development of HuperTacrines as non-toxic, cholinesterase inhibitors for the potential treatment of Alzheimer’s disease

Mourad Chioua, Marta Pérez, Oscar M. Bautista-Aguilera, Matilde Yañez, Manuela G. López, Alejandro Romero, Ramón Cacabelos, Raimon Puig de la Bellacasa, Simone Brogi, Stefania Butini, José I. Borrell, Jose Marco-Contelles

Research output: Indexed journal article Reviewpeer-review

13 Citations (Scopus)

Abstract

This paper describes our preliminary results on the ADMET, synthesis, biochemical evaluation, and molecular modeling of racemic HuperTacrines (HT), new hybrids resulting from the juxtaposition of huperzine A and tacrine for the potential treatment of Alzheimer’s disease (AD). The synthesis of these HT was executed by Friedländer-type reactions of 2-amino-6-oxo-1,6-dihydropyridine-3-carbonitriles, or 7-amino-2-oxo-1,2,3,4-tetrahydro-1,6-naphthyridine- 8-carbonitriles, with cyclohexanone. In the biochemical evaluation, initial and particular attention was devoted to test their toxicity on human hepatoma cells, followed by the in vitro inhibition of human cholinesterases (hAChE, and hBuChE), and the kinetics/mechanism of the inhibition of the most potent HT; simultaneous molecular modeling on the best HT provided the key binding interactions with the human cholinesterases. From these analyses, (±)-5-amino-3-methyl- 3,4,6,7,8,9-hexahydrobenzo[b][1,8]naphthyridin-2(1H)-one (HT1) and (±)-5-amino-3-(2,6-dichlorophenyl)-3,4,6,7,8,9- hexahydrobenzo[b][1,8]naphthyridin-2(1H)-one (HT3) have emerged as characterized by extremely low liver toxicity reversible mixed-type, selective hAChE and, quite selective irreversible hBuChEIs, respectively, showing also good druglike properties for AD-targeted drugs.

Original languageEnglish
Pages (from-to)648-658
Number of pages11
JournalMini-Reviews in Medicinal Chemistry
Volume15
Issue number8
DOIs
Publication statusPublished - 1 May 2015

Fingerprint

Dive into the research topics of 'Development of HuperTacrines as non-toxic, cholinesterase inhibitors for the potential treatment of Alzheimer’s disease'. Together they form a unique fingerprint.

Cite this